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Abstract   
 
Background:  Subclinical hypothyroidism (SCH) is defined as an elevation in thyroid 
stimulating hormone (TSH), in the absence of reductions in free thyroxine (FT4). An 
estimated 4.6 to 8.6 million Americans meet the criteria for SCH, but are without a 
significant symptom burden. Carotid artery intima media thickness (CIMT) assessment 
with ultrasound technology is a non-invasive modality to assess atherosclerosis and 
cardiovascular health. Research has demonstrated increases in CIMT in subjects with 
overt hypothyroidism at baseline; however, following levothyroxine therapy, CIMT was 
reduced. The objective of this literature review is to determine if levothyroxine treatment 
results in CIMT reduction in adult subjects with subclinical hypothyroidism.  
Methods:  An extensive literature search was performed using MEDLINE, CINAHL, 
Google Scholar and ISI Web of Science. Studies were selected for analysis based on the 
following inclusion/ exclusion criteria: published in the English language, human 
subjects, since 1998 and assessing subclinical hypothyroid and carotid artery intima 
media thickness. Four studies met the criteria and were included in the analysis.  
Results:  The four studies analyzed indicated that treatment with levothyroxine resulted 
in a significant decrease in CIMT in subjects with SCH. Correlations were found between 
CIMT and lipid profile variables. Additionally, age, LDL-C, systolic blood pressure, and 
anti-thyroglobulin antibodies were important predictors of CIMT variation.  
Conclusion:  Treatment of subclinical hypothyroidism with levothyroxine decreases 
carotid artery intima media thickness, which is an important measure of atherosclerosis 
and cardiovascular risk. Although debate still exists whether SCH should be screened for, 
and treated in clinical practice, considerations should be made based on the 
cardiovascular risk and history of the patient on an individual basis.  Additional 
randomized controlled trials with a greater number of subjects are needed to further 
investigate the effects of SCH treatment on CIMT and other cardiovascular markers. 
Moreover, research is needed to further illuminate the long-term effects of SCH treatment 
and cardiovascular risks and events. 
Keywords:  Subclinical hypothyroidism, carotid artery, thyroid replacement therapy 
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The Effectiveness of Thyroid Hormone Replacement Therapy on Carotid 
Artery Intima Media Thickness in Adult Patients With Subclinical 
Hypothyroidism 
 
BACKGROUND 
Overview 
The thyroid gland is critical to the proper functioning and regulation of various 
physiological pathways and processes. It relies on, and is directly influenced by, thyroid 
stimulating hormone (TSH) to function. TSH is emitted by the thyrotrope cells of the 
anterior pituitary gland.1, 2 The synthesis and release of TSH is regulated by thyroid 
releasing hormone (TRH) secreted by the hypothalamus. In response to stimulation from 
TSH, the thyroid produces and releases thyroid hormones, primarily l-thyroxine (T4).2 
Once in the serum, the thyroid hormones act, via a negative feedback system, on the 
anterior pituitary gland and hypothalamus to regulate further release of TSH and TRH, 
respectively.2 The clinical diagnosis of hypothyroidism or hyperthyroidism is made 
relative to the serum concentration of the thyroid hormone levels, namely free T4 (FT4). 
However, in the last several decades, the identification of subclinical hypothyroidism, 
defined as an elevation in TSH without a decrease in FT4, has led to the questioning of 
the previously accepted thyroid dysfunction algorithm. Moreover, the relationship 
between clinical hypothyroidism and cardiovascular risk is well documented,2-4 but 
recent research efforts have been aimed at elucidating the effects of subclinical 
hypothyroidism on cardiovascular health.5-10 
Epidemiology of Subclinical Hypothyroidism 
Subclinical hypothyroidism (SCH) is defined as an elevation in TSH in the 
absence of low free T4,1, 5, 6, 11-13. Based on the generally symptom-free nature of SCH, 
 9 
the percentage of the population who meet the clinical diagnostic criteria is difficult to 
determine. A large United States population based study, the National Health and 
Nutrition Examination Survey (NHANES III),12 found that 4.3% of the study population 
met the diagnostic criteria for SCH, with a range from 1.6% to 4.8%, depending on the 
ethnicity of the subjects. Another study of Colorado residents who participated in a health 
fair, found that 9% of subjects met diagnostic criteria for SCH based on laboratory results 
alone.14 Other reviews1, 13 have estimated that 2-8% of the general population, with up to 
16% in women over 60 years old, meet the criteria for SCH.1  
Etiology of Subclinical Hypothyroidism 
The etiology of SCH is the same as that for overt hypothyroidism.1, 2 The majority 
of SCH cases are a result of autoimmune, or Hashimoto’s, thyroiditis, where laboratory 
results demonstrate elevated levels of anti-thyroid peroxidase (TPO) antibodies.2, 15 Other 
causes include treatment for hyperthyroidism, specifically surgical intervention and 
radioactive iodine administration, or pharmacological agents used in the treatment of 
other medical conditions, such as lithium, iodine, phenylbutazone and sulfonamides.1, 2 
Debate still exists in the medical community over the likelihood of patients with 
SCH developing overt hypothyroidism with time. One review reports that 20% to 50% of 
people will develop overt hypothyroidism within four to eight years following initial 
laboratory evidence of SCH.1 Fatourechi13 described more specific criteria and stated that 
a TSH level greater than 10mIU/L is more predictive of progression to overt 
hypothyroidism than a TSH level less than 6mIU/L.  
Carotid Artery Intima Media Thickness as a Marker for Cardiovascular Health 
 10 
Carotid artery intima media thickness (CIMT), measured by ultrasound, has been 
identified as a surrogate variable to assess the likelihood of cardiovascular event 
occurrence and cardiovascular health in general.16-19 A study done by Baldassarre et 
al18found a correlation between CIMT and the number of cardiovascular risk factors. 
Furthermore, the researchers18 were able to identify the subjects with previous 
cardiovascular events, including peripheral artery disease (PAD) and congestive heart 
failure (CHF), using the data from the CIMT ultrasound. Bots et al17, 19 demonstrated that 
increased CIMT and carotid plaques are markers of increased risk of stroke, coronary 
heart disease and death over a 10-12 year period in subjects 55 years and older. 
Assessment of CIMT via ultrasonography has become regarded as a relatively 
inexpensive, yet informative, modality to evaluate cardiovascular health and the 
likelihood of cardiovascular events.18 
Carotid Artery Intima Media Thickness and Hypothyroidism 
Research has been conducted to examine the relationship between carotid artery 
intima media thickness (CIMT) in patients with overt hypothyroidism. Nagasaki et 
al20demonstrated that, in patients with overt, untreated hypothyroidism, CIMT was 
significantly higher at baseline when compared to age and gender matched euthyroid 
controls. After one year of treatment with levothyroxine, the hypothyroid patients had a 
significant reduction in CIMT, such that they were comparable to matched controls.20  
Subclinical Hypothyroidism and Cardiovascular Health 
An estimated 4.6 to 8.6 million Americans meet the clinical diagnosis guidelines 
for SCH without a significant symptom burden that would prompt a visit to their 
practitioner.21 Despite lack of symptoms, treatment of SCH may be indicated based on 
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the physiological effects that elevated TSH may have. The relationship between TSH 
elevations and cardiovascular health has been well documented; nonetheless, debate still 
exists when considering subjects with SCH.2-6, 14, 22 Hak et al5 reported that SCH is 
independently associated with increased aortic atherosclerosis and myocardial infarction 
rate in a population based study of older women. A study by Walsh et al23 demonstrated 
that SCH is an independent predictor of coronary heart disease and patients with SCH 
had significantly more fatal and non-fatal coronary heart disease events than their 
euthyroid controls.23  
In contrast, a study by Rodondi et al22 found that elderly patients with SCH did 
not have increased coronary heart disease events, strokes, PAD, cardiovascular mortality, 
or total mortality when compared to euthyroid controls. The researchers22 did find higher 
total cholesterol levels and increased incidence and recurrence of CHF in SCH subjects.  
In general, studies point towards increased cardiovascular risks with SCH, but the 
risks of untreated SCH and the decision to treat continues to be a topic of debate in the 
medical community. 
Purpose of Study 
 Research has illustrated that both overt and subclinical hypothyroidism have 
negative effects on cardiovascular markers and health.2-5, 14 The use of ultrasound to 
determine carotid artery intima media thickness has come to be accepted as a cost 
effective way to investigate cardiovascular health and risk of cerebrovascular and 
cardiovascular events. It has been shown20 that treatment with thyroid replacement 
hormone significantly reduces CIMT in patients with overt hypothyroidism. However, 
clinical guidelines for the treatment of SCH have largely ignored the issue of CIMT. The 
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purpose of this paper is to perform a systematic review of the literature to determine if 
treating patients with subclinical hypothyroidism will lead to decreased carotid artery 
intima media thickness, and thereby improve cardiovascular health and reduce in the risk 
of events.  
Clinical Question 
 Treatment of SCH is an ongoing debate in the medical community, therefore it is 
important to examine the effects that elevated TSH can have on the cardiovascular 
system and the outcomes that result from SCH treatment using thyroid hormone 
replacement therapy.  
METHODS 
Search Strategy 
 A systematic review of the literature was completed by performing an exhaustive 
search of MEDLINE, Google Scholar, ISI Web of Science, and CINAHL using the 
MeSH terms hypothyrodism, carotid artery, and therapeutics. Additional searches using 
more specific, non-MeSH terms, specifically subclinical hypothyroidism and 
levothyroxine, were also completed. Original research articles examining the effects of 
thyroid replacement medications on carotid artery intima media thickness in patients with 
diagnosed subclinical hypothyroidism were included in this review. Randomized 
controlled trials, cohort studies and case control studies were included. Meta-analyses 
and case reports were excluded. Four studies met the inclusion criteria and were obtained 
and analyzed for valid and significant results. Investigation of the bibliographic 
information in the four articles was completed to ensure an exhaustive search.  
Inclusion/ Exclusion Criteria 
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 Studies examined were limited to those done in adult subjects, published in the 
English language, within the last 12 years. Studies were excluded if thyroid replacement 
therapy was compared to a different class of pharmaceutical agent, or if patients were 
diagnosed with overt hypothyroidism. 
After considering these criteria, four articles were appraised using an original, 
seven point scoring system designed to evaluate the validity and quality of the studies. 
The criteria included two questions from the Jadad scoring guidelines and five additional 
questions. These additional questions were designed to assess homogeneity of subjects in 
specific measures between and within studies, quality definitions and measurements of 
the variables of interest, and the awareness and/or assessment of confounding variables. 
There was no minimum score needed, therefore, all four studies were reviewed and 
included. See Table 1 for the appraisal criteria score.  
RESULTS 
 A thorough exploration of the literature, followed by appraisal of the validity and 
quality of the studies yielded the articles that were examined for this systematic review.  
See Table 2 for a summary of the articles included. One study included is a double blind, 
placebo-controlled trial and the remaining three studies are cohort studies, specifically 
therapy/ prevention designs. Sample size ranged from 57-112 subjects. The duration of 
time between obtaining TSH normalization in the treatment groups and reassessing study 
variables ranged from four months to 18 months. All four studies demonstrated 
significant reductions in carotid artery intima media thickness (CIMT) in subjects treated 
with levothyroxine (L-T4). The studies were individually evaluated using the 
aforementioned appraisal criteria score. 
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A randomized controlled trial by Monzani et al7 was conducted at the University 
of Pisa in Italy and published in the Journal of Clinical Endocrinology and Metabolism. 
The design was a double-blind, placebo-controlled study to examine the effects of 
levothyroxine (L-T4) treatment on carotid artery intima media thickness (CIMT) and 
lipid profiles in subjects with subclinical hypothyroidism (SCH).7 Subjects with SCH 
were recruited from the outpatient clinic of the Internal Medicine department and were 
selected based on a TSH >3.6mIU/L for at least six months before the study. A total of 45 
SCH subjects (37 female) were enrolled in the study; 36 were positive for anti-thyroid 
peroxidase (TPO) antibodies, and nine had received radioiodine therapy for multinodular 
toxic goiter or toxic adenoma. Thirty-two euthyroid control subjects (27 female) were 
selected from staff and relatives of SCH subjects. The control participants were matched 
based on sex, age and BMI. All euthyroid subjects had normal thyroid function tests and 
were negative for TPO antibodies, which indicates lack of thyroid dysfunction. All 
subjects were in good health, had normal routine chemistry laboratory studies, and were 
not taking medications.  Subjects were excluded if they were postmenopausal or 
pregnant, 55 years or older, obese, smokers, had hypertension, diabetes mellitus, renal or 
hepatic failure, or other systemic diseases.7 This study was the only randomized 
controlled trial that met the inclusion criteria for this review and it received a 7 out of 7 
on the appraisal criteria score.  
 At the initiation of the study, fasting laboratory values were obtained on all 
subjects, and CIMT was evaluated using ultrasonography. A total of eight segments from 
the left and right common carotid arteries were averaged to obtain the mean CIMT and 
the maximum thickness of any of the eight segments was measured for use in analysis.  
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 Subsequent to baseline measurements, SCH participants were randomized to 
receive levothyroxine (L-T4) replacement therapy (n=23) or placebo (n=22). The 23 
subjects receiving L-T4 therapy were started with 25 µg and had repeat thyroid function 
testing done every three months. Levothyroxine dosage adjustments were made in 25 µg 
increments if TSH remained above 3.6 mIU/L. Laboratory tests were repeated quarterly 
until TSH normalization was reached. The 22 placebo subjects also had repeat laboratory 
testing every three months and some subjects received additional placebo pills to 
maintain blindness. All subjects underwent repeat CIMT measurement and fasting 
laboratory work after six months of TSH normalization in L-T4 replacement subjects and 
six months following the last dosage assignment in the placebo subjects. 
 At baseline, the SCH participants (n=45) had significantly elevated mean CIMT 
compared to euthyroid controls. In the analysis, the SCH subjects were stratified into two 
groups, under 35 years old and over 35 years old, in order to account for age effects on 
CIMT. When analyzed in separate groups, the mean CIMT of the older group remained 
significantly greater than the euthyroid controls; however, the mean CIMT in the younger 
group no longer varied significantly from the euthyroid controls. The SCH group had 
significantly elevated total cholesterol and LDL-C compared to euthyroid controls.  
After six months of TSH normalization, the L-T4 subjects sustained significant 
reductions in mean CIMT, with a mean reduction of 0.09 mm or 10% (95% CI 0.06-
0.11).7 While mean CIMT was reduced in the L-T4 treated subjects, the group (n=45) did 
not reach the levels of the euthyroid controls during the study period. However, when 
stratified by age, the younger group obtained mean CIMT equivalent to euthyroid 
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controls. Levothyroxine treated subjects also illustrated significant reductions in total 
cholesterol and LDL-C.  
When comparing the SCH L-T4 treated subjects with the SCH placebo subjects, 
there were no significant differences in laboratory results or CIMT measurements at 
baseline. Following six months of stable TSH normalization, the mean-CIMT of the L-T4 
treated participants was significantly lower than the placebo treated group (p=0.03).7 
Significance remained when subjects were analyzed in separate age groups as well.  
Additional analyses revealed that 46% of the variation in mean CIMT was 
accounted for by age, and that absolute reductions in mean CIMT were directly related to 
decreases in absolute total cholesterol and in TSH values.  
Monzani et al7 concluded that treatment with levothyroxine reduces carotid artery 
intima media thickness and improves lipid profiles in subjects with subclinical 
hypothyroidism. Additionally, the researchers7 reported strong evidence to suggest that 
age is an influential determinant of CIMT. 
Kim et al8 published results of a cohort study in Endocrine Journal. The study 
was designed to determine if subclinical hypothyroidism is associated with increased 
carotid artery intima media thickness (CIMT) and if levothyroxine treatment reduces 
CIMT and improves lipid profiles. In this study, the researchers included three subject 
groups: newly diagnosed subclinical hypothyroid (TSH >5.5 mIU/L with a normal FT4 
between 11.4 and 22.6 pmol/L), overt hypothyroid (TSH >5.5 mIU/L with a free T4 
(FT4) <11.4 pmol/L), and euthyroid control subjects (normal TSH between 0.35 and 5.50 
mIU/L and a normal FT4 between 11.4 and 22.6 pmol/L).8 Both thyroid dysfunction 
groups were recruited consecutively from an outpatient clinic in Korea and were 
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determined to have thyroid dysfunction following a minimum of two abnormal thyroid 
function laboratory tests conducted at least two months apart. Additionally, thyroid 
dysfunction subjects were required to have positive anti-thyroid peroxidase (TPO) 
antibodies and evidence of Hashimoto’s thyroiditis on thyroid ultrasound. At the start of 
the study, there were 36 SCH subjects (31 female), 40 overt hypothyroid subjects (36 
female) and 32 euthyroid control subjects (27 female). The healthy, euthyroid control 
subjects were matched based on age, gender and BMI. Subjects were excluded from the 
study if they had previous thyroid disease and underwent treatment, diabetes mellitus, 
hypertension, elevated creatinine, were smokers, or were taking medications that affect 
the lipid profile. Additionally, female subjects were excluded if they were currently or 
previously pregnant within the last year, or were postmenopausal.8The study received a 5 
out of 7 on the appraisal criteria score due to the inability to assess if SCH subjects met 
the three-month duration requirements for SCH diagnosis and the fact that the subjects 
were not randomized.  
Before initiating levothyroxine (L-T4) treatment, all subjects underwent a detailed 
medical history, physical exam, fasting laboratory studies of glucose and lipid profile, 
and carotid artery assessment.  Carotid arteries were scanned using ultrasonography and 
the mean CIMT was calculated using the values of 99 computer-based points within a 
region of the common carotid artery.  
After baseline measurements, all hypothyroid subjects were started on L-T4, 
which was adjusted periodically to maintain TSH and FT4 levels within the reference 
ranges. All tests were repeated in the SCH group after one year of TSH normalization, 
which was, on average, 18 months after initiation of L-T4.8 Of the 36 SCH at the start of 
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the study, 28 completed the follow-up; three were lost to follow up, four transferred to 
other institutions and one refused follow-up CIMT measurement.  
The researchers8 reported that age, gender, BMI, waist circumference and HDL-C 
were similar across all three groups at baseline. In contrast, participants with SCH had 
significantly higher CIMT, total cholesterol and LDL-C than euthyroid controls at 
baseline. The CIMT in subjects with overt hypothyroidism did not differ significantly 
from that of SCH subjects.  Analyses illustrated that CIMT was associated with age, 
systolic blood pressure, glucose, total cholesterol, LDL-C and triglycerides.8 After 12 
months of TSH normalization, the SCH subjects had significant decreases in CIMT, 
averaging 0.07 mm ± 0.06 mm (p=0.021).8 SCH participants also had significant 
reductions in total cholesterol and LDL-C.  
Kim et al8 concluded that subclinical hypothyroidism resulted in increased CIMT 
associated with disturbances in the lipid profile; however, levothyroxine treatment 
decreased CIMT and improved lipid profiles and thereby, slowed and possibly prevented 
atherosclerosis. 
In a cohort design study by Kebapcilar et al9 published in Medical Science 
Monitor, CIMT and other measures of cardiovascular health were compared in euthyroid 
control subjects and subjects with subclinical hypothyroidism (SCH), both before and 
after levothyroxine (L-T4) treatment. The study was conducted between January and 
November 2007 at University Hospital of Dokuz Eylul University in Izmir, Turkey. It 
compared 38 SCH subjects (31 female) mean age 49.79 ± 10.04 years and 19 euthyroid 
control subjects (12 female) mean age 49.95 ± 8.12 years. Of the 38 SCH subjects, 24 
had autoimmune thyroiditis, 10 had subtotal resection of multinodular goiter, and 4 had 
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SCH of unknown etiology. The authors defined SCH as a TSH > 5.0 mIU/L with a 
normal free T4 level between 0.8 and 1.9 ng/dL on two separate laboratory studies at 
least two months apart. Subjects were excluded from the study if they were diabetic, had 
cardiac, renal, hepatic or other systemic diseases, were morbidly obese, had familial 
hyperlipidemias, had a history of malignancy, or were taking antihyperlipidemic 
medications, antihypertensive agents, aspirin, antihistamines, corticosteroids, hormone 
replacement medications, multivitamins, or were consuming excessive amounts of 
alcohol. The control subjects underwent history, physical exam and laboratory chemical 
analysis to ensure lack of disease prior to enrollment. The study earned a 4 out of 7 on the 
appraisal criteria score due to the fact that subjects were not gender matched, failure to 
randomize subjects, and an inadequate duration of SCH diagnosis.  
All study subjects had fasting laboratory studies done at baseline and the SCH 
subjects had repeat studies three months after TSH normalization was reached, which 
was an average of six months after initiation of L-T4. Carotid artery intima media 
thickness (CIMT) of the right and left common carotid arteries was measured in three 
non-neighboring locations using ultrasonography. The mean value was calculated for an 
average CIMT in all subjects at baseline.  The SCH subjects had repeat CIMT 
measurements taken an average of six months after treatment with L-T4. The SCH and 
control subjects were matched based on age, smoking habit, waist circumference and 
BMI.  
All SCH subjects were placed on L-T4 following baseline evaluation. 
Levothyroxine treatment was taken orally and was initiated at 25-50 µg in all SCH 
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subjects; the dose was increased every four weeks, as needed, following reevaluation of 
TSH levels.9  
At baseline, the mean CIMT of the SCH subjects was significantly higher than the 
controls. Following treatment and TSH normalization in the SCH subjects, there were 
significant reductions in mean CIMT, total cholesterol, and HDL-C. The average 
reduction in CIMT was 0.01 mm (p = 0.008), but despite reductions in CIMT, the SCH 
subjects did not reach thicknesses equivalent to those of euthyroid controls.9 Additional 
statistical analyses revealed that age and anti-thyroid antibodies were significant 
predictors of elevated CIMT in SCH subjects. Furthermore, it was demonstrated that 
reductions in CIMT were independent of lipid profile changes.  
Kebapcilar et al9 concluded that L-T4 treatment reduced mean CIMT, and thereby 
decreased atherosclerotic risk in subjects with subclinical hypothyroidism. 
Andrees et al10 conducted a cohort study designed to examine the effects of 18 
months of levothyroxine treatment on women with subclinical hypothyroidism. The study 
was published in Clinical Endocrinology. Subjects with SCH were identified during 
routine thyroid function tests and were referred by a general practice to a tertiary referral 
hospital, where they underwent further screening to determine eligibility for the study. To 
be included, SCH subjects had to be females between the ages of 30 and 60, with 
consistently elevated TSH and normal free T4 levels for at least six months, and be non-
smokers, free of the following: hypertension, diabetes mellitus, impaired fasting glucose 
or a history of ischemic heart disease or transient ischemic attacks. Control subjects were 
recruited from the general population, were not taking any medications, and were free of 
any diseases.10 At the start of the study, 56 SCH and 56 age and BMI matched control 
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subjects were enrolled; however, four subjects in the SCH cohort were not included in the 
analysis due to celiac disease (n=1), pernicious anemia (n=1) and need for 
antihypertensive therapy (n=2) that occurred during the study. Of the 56 SCH subjects, 
42 had positive anti-thyroid peroxidase antibodies, indicating autoimmune thyroiditis, the 
remaining 14 had SCH of an unidentified origin. Additionally, eight of the control 
subjects had positive anti-thyroid peroxidase antibodies, but did not display other signs of 
autoimmune thyroiditis, namely, elevated TSH. This study received a 4 out of 7 on the 
appraisal criteria score because there was no discussion or statistical analysis of potential 
confounding variables that could have affected or accounted for changes in CIMT, 
subjects were not randomized into study groups, and the authors failure to provide normal 
reference ranges for TSH and free T4 levels according to the laboratory used.  
All study subjects (56 SCH, 56 control) underwent laboratory testing to assess 
cardiovascular risk factors at baseline and the 52 remaining SCH subjects who completed 
18 months of levothyroxine (L-T4) had repeat testing following treatment. Carotid artery 
intima media thickness (CIMT) was measured at baseline in 20 SCH subjects, who did 
not differ significantly from the other 36 SCH subjects. Using ultrasound technology, a 
mean value was calculated with three measurements from the right and left common 
carotid arteries. CIMT measurements were repeated in the same 20 subjects following 18 
months of L-T4 treatment.10 CIMT was not measured in control subjects at either time 
point in this study. 
Following baseline assessments, all SCH subjects were started on 50 µg of L-T4. 
TSH was reassessed every three months and L-T4 dosage adjustments made accordingly 
in order to reach TSH normalization.  
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Adrees et al10 reported that mean CIMT was significantly reduced following 18 
months of L-T4 treatment in the 20 SCH subjects evaluated. Mean CIMT across the 
subjects decreased by 0.11 mm or 12% (p=0.046).10  At baseline, SCH subjects had 
significantly higher markers of cardiovascular risk including total cholesterol, LDL-C, 
and systolic and diastolic blood pressure when compared to euthyroid control subjects. 
Following treatment, the SCH subjects had decreases in all of the aforementioned 
variables and were no longer significantly different from their matched controls.  
The authors10 concluded that 18 months of levothyroxine treatment in subjects 
with SCH resulted in decreases of CIMT that were associated with reductions in 
additional cardiovascular risk markers. 
DISCUSSION 
 The aim of this systematic review was to analyze the current literature to 
determine whether thyroid hormone replacement therapy reduced CIMT in adults with 
subclinical hypothyroidism. All four studies analyzed in this review concluded that 
treatment of SCH with levothyroxine resulted in significant decreases in CIMT.7-10 
Furthermore, improvements in lipid profiles were seen in all four studies as a result of L-
T4 treatment. The combination of decreased CIMT and improved lipid profiles led the 
researchers to draw the conclusion that levothyroxine treatment lowers cardiovascular 
risk, specifically atherosclerosis, in subjects with SCH.7-10 
 Each of the studies measured additional variables that were not included in the 
analysis for this review, and therefore not addressed in the results section.  
 Carotid artery intima media thickness measurement is a noninvasive, efficient and 
relatively low-cost modality to evaluate cardiovascular health and risk.16, 18 Yet, 
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traditionally, laboratory lipid studies have been used to assess these measures. The four 
studies7-10  analyzed included both CIMT measurements and lipid profiles in their 
protocols and three of the studies determined the statistical relationship between the 
variables.7-9  Monzani et al7 and Kim et al8reported that the reduction in CIMT was 
directly related to the decrease in total cholesterol and LDL-C, respectively. Kebapcilar et 
al9 demonstrated significant decreases in LDL-C, but did not discuss these decreases in 
the context of CIMT reductions. Three of the research teams7-9  identified age as a 
significant predictor of CIMT variability, specifically increasing age as it relates to 
greater CIMT. In fact, Kim et al8 and Monzani et al7 reported that age accounted for 64% 
and 46% of the variation in CIMT, respectively. Other factors that explained variability 
in CIMT included TSH7, LDL-C7, 8, systolic blood pressure8, and anti-thyroglobulin 
antibodies9. 
 Of the four studies examined in this review, three studies explicitly state either 
their funding9or that the authors do not have conflicts of interest8or disclosure of note10. 
However, Monzani et al7 do not mention their source of funding or report conflicts of 
interest. When considering the results of a pharmacological study, it is important to 
consider the funding of the research and notable conflicts of interest of the authors.  
Limitations of Studies 
 While there are clinically relevant outcomes in each of the studies analyzed in this 
review, it is important to consider the limitations of the research.  
 One important limitation of all of the included studies7-10 was the small sample 
sizes. The number of subjects with subclinical hypothyroidism in each of the studies 
ranged from 368 to 5610. However, in the study10 with 56 SCH subjects, only 20 
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underwent CIMT measurements. Although none of the studies had large drop out rates, a 
greater number of subjects would increase statistical power and possibly the clinical 
relevance of the results. 
 Each of the studies7-10 included a euthyroid control group that was used for pre-
treatment comparison and had laboratory and CIMT measurements done at baseline. 
However, none of the studies performed repeat testing in the euthyroid control groups 
following four to 18 months of levothyroxine treatment in the SCH participants. 
Kebapcilar et al9, Andrees et al10, and Monzani et al7 compared both SCH pre- and SCH 
post-treatment data to euthyroid controls, but used baseline measurement for euthyroid 
control subjects. The trepidation about using baseline data to compare with post-
treatment data is the likelihood of change in baseline data over the course of the study 
intervention. In one study,10 18 months elapsed between baseline and post-treatment 
measurements which could be time enough for CIMT and lipid variable to change.  
 Three of the reviewed studies8-10 used cohort, within-subject designs, as opposed 
to randomized controlled trials. While the participants in these studies were used as their 
own controls following treatment, all of them received levothyroxine making the placebo 
effect a possible confounder. Furthermore, Kim et al8 performed only pre- and post-
treatment analyses in the SCH group and did not include post-treatment comparisons to 
overt hypothyroid or euthyroid control subjects.  
 Kim et al8 required two abnormal TSH levels at least two months apart, making 
the exact timeline difficult to interpret. Likewise, in the study by Kebapcilar et al,9 
subjects were considered to have SCH if they had laboratory evidence of elevated TSH 
for two months. It is documented2 and generally accepted in clinical practice, that 
 25 
patients should have an elevated TSH for at least three months before considering a 
thyroid dysfunction diagnosis and subsequent treatment. Therefore, time until diagnosis 
was inadequate9 or impossible to determine8 in the two aforementioned studies.  
Andrees et al10 included eight subjects with evidence of autoimmune thyroid 
disease, specifically positive anti-thyroid peroxidase (TPO) antibodies, in their control 
group. TPO antibodies are evidence of thyroid dysfunction and thereby, those eight 
subjects had the potential to distort the picture of euthyroid controls, particularly when 
considering the small sample size. Additionally, the normal reference ranges for the 
thyroid function laboratory tests were not included in their paper. Without these values, it 
is difficult to determine if subjects, in fact, met laboratory criteria for SCH and 
euthyroidism. Lastly, Andrees et al10 did not include any statistical analysis or discussion 
of the influence that other study variables, such as age or lipid profile values, had on 
CIMT. As seen in the other studies,7-9 these variables were statistically related to and 
accounted for portions of the CIMT changes.  
Andrees et al10 and Kebapcilar et al9 did not indicate if the women in the study 
were pre- or post-menopausal. Menopause is associated with many physiological changes 
and thyroid function is possibly one of them. In fact, one study1 found that up to 16% 
women 60 years and older meet criteria for subclinical hypothyroidism. Additionally, 
research2 has demonstrated that menopause can affect both thyroid function and coronary 
disease, both of which were critical variables in this review. Therefore, it is important to 
indicate menopause status when considering thyroid function and cardiovascular health.  
Similarly, Kebapcilar et al9 did not gender match the subjects for analysis. While 
the remaining three gender-matched studies7, 8, 10 did not report results separated by 
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gender, it has been documented that both thyroid disorders and coronary disease2 differ in 
incidence based on sex. Therefore, to decrease the influence of subject gender on results, 
subjects should be matched between the euthyroid and the control groups.  
Lastly, all four studies7-10 used the mean of between three and 99 measurements 
of carotid artery intima media thickness (CIMT) to be used in analysis. While statistically 
this may have been the most reasonable method to obtain a single number to represent 
CIMT, the value could have been distorted in either direction. Importantly, the value of 
CIMT used in analysis could have been low or normal in a given patient despite an area 
with large amounts of plaque that could potentially harmful in the near future. This is an 
important ethically issue to consider when deciding on treatment or intervention in an 
individual patient.  
Future Research 
 Additional studies to investigate the correlation between subclinical 
hypothyroidism and cardiovascular health are indicated. As evidenced by the studies 
examined in this review, larger sample sizes are needed in order to increase both 
statistical power and clinical significance. Moreover, additional randomized controlled 
trials would strengthen the evidence of the relationship between thyroid replacement 
treatment and reductions in cardiovascular risk factors in subjects with SCH.  
 The current number of Americans with untreated SCH21 begs the questions of cost 
to treat them and more importantly, the long-term risk reduction in cardiovascular events 
that would follow. A longitudinal study aimed at investigating these outcomes would be 
useful when considering the cost-benefit ratio of treatment in clinical practice.  
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 The intentions of this review are not to advise clinicians to use carotid artery 
ultrasonography as a means to diagnose or assess the severity of thyroid dysfunction in 
patients. Rather, it is to demonstrate, using CIMT as a surrogate variable, that subclinical 
hypothyroidism has detrimental effects on cardiovascular health that can be slowed or 
reversed with levothyroxine treatment. While treatment may not be indicated in all 
patients with laboratory diagnosed subclinical hypothyroidism, clinicians should consider 
the patients on an individual basis and include important historical information in the 
decision to treat.  
CONCLUSION 
The decision to screen for and treat subclinical hypothyroidism remains a 
question of debate in the medical community.24 There is evidence that thyroid hormone 
replacement therapy decreases carotid artery intima media thickness in subjects with 
subclinical hypothyroidism, as illustrated by this literature review. However, the cost and 
long-term outcomes of treatment in the estimated 4.6-8.6 million Americans that meet 
laboratory criteria for SCH should be considered. While there is a need for further 
research to assist in the decision to treat, it is ultimately a clinician’s duty to consider 
each patient as an individual and to take into account pertinent family and personal 
history, as well as other existing cardiovascular risk factors. 
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TABLES 
Table 1. Appraisal Scoring Criteria 
Criteria  Yes (1) No (0) 
Was the study described as randomized*? 
 
  
Was there a description of withdrawals and dropouts*? 
 
  
Did the subjects have an elevated TSH or diagnosis of subclinical 
hypothyroidism for at least 3 months prior intervention? 
  
Did subjects meet the laboratory criteria for subclinical 
hypothyroidism (elevated TSH and normal Free T4) respective to the 
study? 
  
At baseline, were subjects’ age and gender matched between groups? 
   
Were at least 3 measurements of carotid intima media thickness used 
to obtain a mean value utilized in analyses?   
Were the effects of pertinent confounding variables discussed and/or 
adjusted for with regards to carotid artery intima media thickness? 
  
*Part of Jadad score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32 
Table 2. Summary of Reviewed Articles 
Author(s), 
Study Type, 
& 
Year 
Published 
Subjects Intervention 
Comparison 
between 
Subjects 
Outcome(s) Appraisal Criteria Score, out of 7 Comments 
Monzani et al7 
Randomized 
Controlled 
Trial 
 2004 
• 45 (37 female) 
SCH subjects; 
Mean age 37 ± 11 
yrs. Divided into 
>35 yrs & <35 yrs 
for some analyses 
 
 
 
• 32 (27 female) 
euthyroid controls; 
Mean age 35 ± 10 
yrs.  
• L-T4 at 25μg; 
titrated every 3 
months as needed 
(n=23) 
                OR 
• Placebo; similar 
titration (n=22) 
 
 
• None 
 
CIMT (mm) 
 
Significant ↓in CIMT in 
L-T4 treated SCH 
subjects compared to 
control (mean = 
0.09mm, 95% CI: 0.06-
0.11) 
 
Significant ↓ in CIMT 
in L-T4 treated SCH 
subjects <35 yrs equal 
to controls  
 
7/7 At baseline, CIMT 
significantly 
higher in >35 yrs 
SCH compared to 
euthyroid controls 
 
Kim et al8 
Cohort 
2009 
• 36 (31 female) 
SCH subjects; 
Mean age 36.0 ± 
6.2 yrs. 
 
• 40 (36 female) 
overt hypothyroid 
subjects; Mean 
age 37.8 ± 6.3 yrs. 
  
• 32 (27 female) 
euthryoid controls; 
Mean age 36.1 ± 
5.4 yrs. 
 
 
 
•L-T4; adjustments 
made on individual 
basis  
 
 
 
 
• None 
 
 
 
CIMT (mm) 
 
 
 
Significant ↓ in CIMT 
in SCH subjects (mean 
= 0.07mm, p=0.021) 
 
 
5/7  
Failure to randomize; 
Unable to determine 
duration of SCH 
diagnosis before 
study 
 
Starting L-T4 
doses and time 
between 
adjustments not 
provided 
 
Kebapcilar et 
al9 
Cohort 
2010 
• 38 (31 female) 
subjects with 
SCH; Mean age 
49.79 ± 10.04 yrs 
 
• 19 (12 female) 
age-matched, 
euthyroid controls; 
Mean age 49.94 ± 
8.12 yrs. 
•L-T4 at 25-50μg; 
titrated every 4 
weeks as needed 
 
 
• None 
 
CIMT (mm) 
 
 
Significant ↓in CIMT in 
SCH subjects (mean = 
0.01mm, p=0.008) 
 
 
 
4/7 
Failure to randomize; 
Only 2 months SCH 
diagnosis; Subjects 
not gender matched 
 
 
Andrees et 
al10 
Cohort 
2009 
• 56 females with 
SCH; Mean age 50 
± 9 yrs. 
 
• 56 age-matched, 
euthyroid female 
controls; Mean 
age 47 ± 8 yrs. 
• L-T4 at 50μg; 
titrated every 3 
months as needed 
 
• None 
 
CIMT (mm) 
 
 
 
Significant ↓ in CIMT 
in SCH subjects (mean 
= 0.11mm, p=0.046) 
 
4/7 
Failure to randomize; 
No normal lab 
reference ranges 
provided; No 
comment of analysis 
of confounding 
variables on CIMT 
8 control subjects 
had + TPO 
antibodies, 
indicating 
autoimmune 
thyroid disease 
 
 
Key: SCH: Subclinical hypothyroidism; L-T4: levothyroxine; CIMT: Carotid artery intima media thickness; TPO: antithyroid peroxidase antibodies 
 
 
 
 
 
